Do analysts rate EAF or NMAD?

GrafTech International currently has a consensus price target of $10.67, indicating a potential downside of 4.04%. Given GrafTech International's stronger consensus rating and higher possible upside, analysts clearly believe GrafTech International is more favorable than Lixte Biotechnology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score GrafTech International 2 Sell rating(s) 4 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67 Lixte Biotechnology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media favor EAF or NMAD?

In the previous week, GrafTech International and GrafTech International both had 3 articles in the media. Lixte Biotechnology's average media sentiment score of 0.98 beat GrafTech International's score of 0.64 indicating that Lixte Biotechnology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GrafTech International 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Lixte Biotechnology 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer NEOV or NMAD?

NeoVolta currently has a consensus price target of $9.50, indicating a potential upside of 333.79%. Given NeoVolta's stronger consensus rating and higher possible upside, research analysts clearly believe NeoVolta is more favorable than Lixte Biotechnology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NeoVolta 1 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.43 Lixte Biotechnology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media favor NEOV or NMAD?

In the previous week, NeoVolta had 33 more articles in the media than Lixte Biotechnology. MarketBeat recorded 36 mentions for NeoVolta and 3 mentions for Lixte Biotechnology. Lixte Biotechnology's average media sentiment score of 0.98 beat NeoVolta's score of -0.24 indicating that Lixte Biotechnology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NeoVolta 2 Very Positive mention(s) 2 Positive mention(s) 10 Neutral mention(s) 0 Negative mention(s) 2 Very Negative mention(s) Neutral Lixte Biotechnology 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer SES or NMAD?

SES AI presently has a consensus target price of $2.55, suggesting a potential upside of 374.86%. Given SES AI's stronger consensus rating and higher possible upside, equities research analysts clearly believe SES AI is more favorable than Lixte Biotechnology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score SES AI 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Lixte Biotechnology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media prefer SES or NMAD?

In the previous week, SES AI and SES AI both had 3 articles in the media. Lixte Biotechnology's average media sentiment score of 0.98 beat SES AI's score of 0.00 indicating that Lixte Biotechnology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment SES AI 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Lixte Biotechnology 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate SKYX or NMAD?

SKYX Platforms currently has a consensus price target of $4.67, suggesting a potential upside of 279.40%. Given SKYX Platforms' stronger consensus rating and higher possible upside, equities research analysts plainly believe SKYX Platforms is more favorable than Lixte Biotechnology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score SKYX Platforms 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.80 Lixte Biotechnology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media refer more to SKYX or NMAD?

In the previous week, SKYX Platforms had 3 more articles in the media than Lixte Biotechnology. MarketBeat recorded 6 mentions for SKYX Platforms and 3 mentions for Lixte Biotechnology. Lixte Biotechnology's average media sentiment score of 0.98 beat SKYX Platforms' score of 0.57 indicating that Lixte Biotechnology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment SKYX Platforms 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Lixte Biotechnology 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer NMAD or EPOW?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lixte Biotechnology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Sunrise New Energy 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable valuation & earnings, NMAD or EPOW?

Lixte Biotechnology has higher earnings, but lower revenue than Sunrise New Energy. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Lixte Biotechnology N/A N/A -$6.01M -$1.00 N/A Sunrise New Energy $46.42M 0.28 -$16.64M N/A N/A

Is NMAD or EPOW more profitable?

Sunrise New Energy's return on equity of 0.00% beat Lixte Biotechnology's return on equity. Company Net Margins Return on Equity Return on Assets Lixte Biotechnology N/A -75.49% -62.03% Sunrise New Energy N/A N/A N/A

Does the media refer more to NMAD or EPOW?

In the previous week, Lixte Biotechnology and Lixte Biotechnology both had 3 articles in the media. Lixte Biotechnology's average media sentiment score of 0.98 beat Sunrise New Energy's score of 0.95 indicating that Lixte Biotechnology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lixte Biotechnology 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Sunrise New Energy 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Lixte Biotechnology (NMAD) Competitors

$3.58 -0.05 (-1.38%)

As of 09/25/2026 04:00 PM Eastern

Compare

NMAD vs. EAF, NEOV, SES, SKYX, and EPOW

Should you buy Lixte Biotechnology stock or one of its competitors? Lixte Biotechnology's main competitors and comparable companies include GrafTech International (EAF), NeoVolta (NEOV), SES AI (SES), SKYX Platforms (SKYX), and Sunrise New Energy (EPOW). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "electrical components & equipment" industry.

How does Lixte Biotechnology compare to GrafTech International?

GrafTech International (NYSE:EAF) and Lixte Biotechnology (NASDAQ:NMAD) are both small-cap industrials companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, media sentiment, valuation, profitability, analyst recommendations, institutional ownership, risk and dividends.

Lixte Biotechnology has a net margin of 0.00% compared to GrafTech International's net margin of -34.58%. GrafTech International's return on equity of 0.00% beat Lixte Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GrafTech International	-34.58%	N/A	-17.50%
Lixte Biotechnology	N/A	-75.49%	-62.03%

Lixte Biotechnology has lower revenue, but higher earnings than GrafTech International. Lixte Biotechnology is trading at a lower price-to-earnings ratio than GrafTech International, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GrafTech International	$512.92M	0.57	-$219.84M	-$6.80	N/A
Lixte Biotechnology	N/A	N/A	-$6.01M	-$1.00	N/A

In the previous week, GrafTech International and GrafTech International both had 3 articles in the media. Lixte Biotechnology's average media sentiment score of 0.98 beat GrafTech International's score of 0.64 indicating that Lixte Biotechnology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GrafTech International	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Lixte Biotechnology	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

92.8% of GrafTech International shares are held by institutional investors. Comparatively, 5.1% of Lixte Biotechnology shares are held by institutional investors. 1.2% of GrafTech International shares are held by insiders. Comparatively, 7.3% of Lixte Biotechnology shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

GrafTech International has a beta of 1.85, indicating that its stock price is 85% more volatile than the broader market. Comparatively, Lixte Biotechnology has a beta of 1.3, indicating that its stock price is 30% more volatile than the broader market.

GrafTech International currently has a consensus price target of $10.67, indicating a potential downside of 4.04%. Given GrafTech International's stronger consensus rating and higher possible upside, analysts clearly believe GrafTech International is more favorable than Lixte Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GrafTech International	2 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Lixte Biotechnology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

GrafTech International beats Lixte Biotechnology on 8 of the 13 factors compared between the two stocks.

How does Lixte Biotechnology compare to NeoVolta?

NeoVolta (NASDAQ:NEOV) and Lixte Biotechnology (NASDAQ:NMAD) are both small-cap industrials companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, earnings, dividends, risk and media sentiment.

Lixte Biotechnology has a net margin of 0.00% compared to NeoVolta's net margin of -161.10%. Lixte Biotechnology's return on equity of -75.49% beat NeoVolta's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NeoVolta	-161.10%	-124.51%	-87.64%
Lixte Biotechnology	N/A	-75.49%	-62.03%

In the previous week, NeoVolta had 33 more articles in the media than Lixte Biotechnology. MarketBeat recorded 36 mentions for NeoVolta and 3 mentions for Lixte Biotechnology. Lixte Biotechnology's average media sentiment score of 0.98 beat NeoVolta's score of -0.24 indicating that Lixte Biotechnology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NeoVolta	2 Very Positive mention(s)	2 Positive mention(s)	10 Neutral mention(s)	0 Negative mention(s)	2 Very Negative mention(s)	Neutral
Lixte Biotechnology	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

NeoVolta has higher revenue and earnings than Lixte Biotechnology. NeoVolta is trading at a lower price-to-earnings ratio than Lixte Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NeoVolta	$13.33M	9.69	-$5.03M	-$0.52	N/A
Lixte Biotechnology	N/A	N/A	-$6.01M	-$1.00	N/A

5.1% of NeoVolta shares are held by institutional investors. Comparatively, 5.1% of Lixte Biotechnology shares are held by institutional investors. 4.0% of NeoVolta shares are held by company insiders. Comparatively, 7.3% of Lixte Biotechnology shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

NeoVolta currently has a consensus price target of $9.50, indicating a potential upside of 333.79%. Given NeoVolta's stronger consensus rating and higher possible upside, research analysts clearly believe NeoVolta is more favorable than Lixte Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NeoVolta	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Lixte Biotechnology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

NeoVolta has a beta of -0.87, meaning that its stock price is 187% less volatile than the broader market. Comparatively, Lixte Biotechnology has a beta of 1.3, meaning that its stock price is 30% more volatile than the broader market.

Summary

NeoVolta beats Lixte Biotechnology on 8 of the 15 factors compared between the two stocks.

How does Lixte Biotechnology compare to SES AI?

SES AI (NYSE:SES) and Lixte Biotechnology (NASDAQ:NMAD) are both small-cap industrials companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, media sentiment, risk, profitability, valuation and earnings.

29.8% of SES AI shares are owned by institutional investors. Comparatively, 5.1% of Lixte Biotechnology shares are owned by institutional investors. 13.8% of SES AI shares are owned by company insiders. Comparatively, 7.3% of Lixte Biotechnology shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

SES AI presently has a consensus target price of $2.55, suggesting a potential upside of 374.86%. Given SES AI's stronger consensus rating and higher possible upside, equities research analysts clearly believe SES AI is more favorable than Lixte Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SES AI	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Lixte Biotechnology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Lixte Biotechnology has a net margin of 0.00% compared to SES AI's net margin of -289.64%. SES AI's return on equity of -26.21% beat Lixte Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SES AI	-289.64%	-26.21%	-20.78%
Lixte Biotechnology	N/A	-75.49%	-62.03%

Lixte Biotechnology has lower revenue, but higher earnings than SES AI. Lixte Biotechnology is trading at a lower price-to-earnings ratio than SES AI, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SES AI	$21M	9.49	-$73.04M	-$0.20	N/A
Lixte Biotechnology	N/A	N/A	-$6.01M	-$1.00	N/A

In the previous week, SES AI and SES AI both had 3 articles in the media. Lixte Biotechnology's average media sentiment score of 0.98 beat SES AI's score of 0.00 indicating that Lixte Biotechnology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
SES AI	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Lixte Biotechnology	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

SES AI has a beta of 1, meaning that its stock price has a similar volatility profile to the broader market.Comparatively, Lixte Biotechnology has a beta of 1.3, meaning that its stock price is 30% more volatile than the broader market.

Summary

SES AI beats Lixte Biotechnology on 10 of the 14 factors compared between the two stocks.

How does Lixte Biotechnology compare to SKYX Platforms?

SKYX Platforms (NASDAQ:SKYX) and Lixte Biotechnology (NASDAQ:NMAD) are both small-cap industrials companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, risk, media sentiment, earnings, institutional ownership, valuation, dividends and profitability.

Lixte Biotechnology has a net margin of 0.00% compared to SKYX Platforms' net margin of -34.34%. SKYX Platforms' return on equity of 0.00% beat Lixte Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SKYX Platforms	-34.34%	N/A	-49.28%
Lixte Biotechnology	N/A	-75.49%	-62.03%

SKYX Platforms has a beta of -3491.36, suggesting that its stock price is 349,236% less volatile than the broader market. Comparatively, Lixte Biotechnology has a beta of 1.3, suggesting that its stock price is 30% more volatile than the broader market.

In the previous week, SKYX Platforms had 3 more articles in the media than Lixte Biotechnology. MarketBeat recorded 6 mentions for SKYX Platforms and 3 mentions for Lixte Biotechnology. Lixte Biotechnology's average media sentiment score of 0.98 beat SKYX Platforms' score of 0.57 indicating that Lixte Biotechnology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
SKYX Platforms	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Lixte Biotechnology	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

SKYX Platforms currently has a consensus price target of $4.67, suggesting a potential upside of 279.40%. Given SKYX Platforms' stronger consensus rating and higher possible upside, equities research analysts plainly believe SKYX Platforms is more favorable than Lixte Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SKYX Platforms	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
Lixte Biotechnology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Lixte Biotechnology has lower revenue, but higher earnings than SKYX Platforms. SKYX Platforms is trading at a lower price-to-earnings ratio than Lixte Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SKYX Platforms	$92.01M	1.81	-$33.42M	-$0.27	N/A
Lixte Biotechnology	N/A	N/A	-$6.01M	-$1.00	N/A

11.8% of SKYX Platforms shares are held by institutional investors. Comparatively, 5.1% of Lixte Biotechnology shares are held by institutional investors. 24.2% of SKYX Platforms shares are held by company insiders. Comparatively, 7.3% of Lixte Biotechnology shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

SKYX Platforms beats Lixte Biotechnology on 11 of the 16 factors compared between the two stocks.

How does Lixte Biotechnology compare to Sunrise New Energy?

Lixte Biotechnology (NASDAQ:NMAD) and Sunrise New Energy (NASDAQ:EPOW) are both small-cap industrials companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, earnings, risk, profitability, dividends, valuation and analyst recommendations.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lixte Biotechnology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Sunrise New Energy	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

5.1% of Lixte Biotechnology shares are owned by institutional investors. Comparatively, 31.9% of Sunrise New Energy shares are owned by institutional investors. 7.3% of Lixte Biotechnology shares are owned by company insiders. Comparatively, 42.5% of Sunrise New Energy shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Lixte Biotechnology has higher earnings, but lower revenue than Sunrise New Energy.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lixte Biotechnology	N/A	N/A	-$6.01M	-$1.00	N/A
Sunrise New Energy	$46.42M	0.28	-$16.64M	N/A	N/A

Sunrise New Energy's return on equity of 0.00% beat Lixte Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lixte Biotechnology	N/A	-75.49%	-62.03%
Sunrise New Energy	N/A	N/A	N/A

In the previous week, Lixte Biotechnology and Lixte Biotechnology both had 3 articles in the media. Lixte Biotechnology's average media sentiment score of 0.98 beat Sunrise New Energy's score of 0.95 indicating that Lixte Biotechnology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lixte Biotechnology	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Sunrise New Energy	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Lixte Biotechnology has a beta of 1.3, indicating that its share price is 30% more volatile than the broader market. Comparatively, Sunrise New Energy has a beta of 0.21, indicating that its share price is 79% less volatile than the broader market.

Summary

Sunrise New Energy beats Lixte Biotechnology on 5 of the 8 factors compared between the two stocks.

Get Lixte Biotechnology News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NMAD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NMAD vs. The Competition

Export

Metric	Lixte Biotechnology	Electrical Equipment Industry	Industrials Sector	NASDAQ Exchange
Market Cap	$57.64M	$10.64B	$10.25B	$13.18B
Dividend Yield	N/A	2.34%	96.95%	14.03%
P/E Ratio	-3.58	45.99	25.32	25.78
Price / Sales	N/A	1,556.05	273.53	74.25
Price / Cash	N/A	34.57	23.99	52.89
Price / Book	3.41	7.48	4.86	6.30
Net Income	-$6.01M	$139.67M	$614.63M	$360.35M
7 Day Performance	-0.83%	0.05%	0.76%	-0.23%
1 Month Performance	-19.00%	-4.11%	-2.77%	-4.16%
1 Year Performance	-29.25%	2.53%	4.25%	4.58%

Lixte Biotechnology Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NMAD Lixte Biotechnology	0.7219 of 5 stars	$3.58 -1.4%	N/A	-29.2%	$57.64M	N/A	N/A	4	News Coverage
EAF GrafTech International	0.6778 of 5 stars	$7.99 -0.2%	$10.67 +33.6%	-19.4%	$208.56M	$504.13M	N/A	1,071	News Coverage Analyst Upgrade
NEOV NeoVolta	2.7743 of 5 stars	$3.44 -1.3%	$9.50 +175.9%	-51.4%	$195.01M	$18.07M	N/A	17	Trending News Earnings Report Analyst Forecast Analyst Revision
SES SES AI	1.7475 of 5 stars	$0.52 -1.7%	$2.55 +387.6%	-71.1%	$193.81M	$23.46M	N/A	215	Analyst Upgrade
SKYX SKYX Platforms	2.7965 of 5 stars	$1.26 -0.4%	$4.67 +271.8%	+7.9%	$169.97M	$96.20M	N/A	73	News Coverage Analyst Upgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NMAD) was last updated on 9/27/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Lixte Biotechnology (NMAD) Competitors

NMAD vs. EAF, NEOV, SES, SKYX, and EPOW

How does Lixte Biotechnology compare to GrafTech International?

Summary

How does Lixte Biotechnology compare to NeoVolta?

Summary

How does Lixte Biotechnology compare to SES AI?

Summary

How does Lixte Biotechnology compare to SKYX Platforms?

Summary

How does Lixte Biotechnology compare to Sunrise New Energy?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NMAD vs. The Competition

Lixte Biotechnology Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Lixte Biotechnology (NMAD) Competitors

NMAD vs. EAF, NEOV, SES, SKYX, and EPOW

How does Lixte Biotechnology compare to GrafTech International?

Is EAF or NMAD more profitable?

Which has stronger earnings & valuation, EAF or NMAD?

Does the media favor EAF or NMAD?

Do institutionals and insiders believe in EAF or NMAD?

Which has more risk and volatility, EAF or NMAD?

Do analysts rate EAF or NMAD?

Summary

How does Lixte Biotechnology compare to NeoVolta?

Is NEOV or NMAD more profitable?

Does the media favor NEOV or NMAD?

Which has higher valuation & earnings, NEOV or NMAD?

Do institutionals & insiders believe in NEOV or NMAD?

Do analysts prefer NEOV or NMAD?

Which has more risk & volatility, NEOV or NMAD?

Summary

How does Lixte Biotechnology compare to SES AI?

Do institutionals & insiders have more ownership in SES or NMAD?

Do analysts prefer SES or NMAD?

Is SES or NMAD more profitable?

Which has higher earnings & valuation, SES or NMAD?

Does the media prefer SES or NMAD?

Which has more risk and volatility, SES or NMAD?

Summary

How does Lixte Biotechnology compare to SKYX Platforms?

Is SKYX or NMAD more profitable?

Which has more volatility and risk, SKYX or NMAD?

Does the media refer more to SKYX or NMAD?

Do analysts rate SKYX or NMAD?

Which has higher valuation and earnings, SKYX or NMAD?

Do insiders & institutionals hold more shares of SKYX or NMAD?

Summary

How does Lixte Biotechnology compare to Sunrise New Energy?

Do analysts prefer NMAD or EPOW?

Do institutionals and insiders believe in NMAD or EPOW?

Which has preferable valuation & earnings, NMAD or EPOW?

Is NMAD or EPOW more profitable?

Does the media refer more to NMAD or EPOW?

Which has more volatility & risk, NMAD or EPOW?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NMAD vs. The Competition

Lixte Biotechnology Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools